We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
7 own
13 watching
Current Price
$4.23
$-0.08
(-1.86%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
281.08M
52-Week High
9.39000
52-Week Low
1.09000
Average Volume
0.57M
Dividend Yield
--
P/E Ratio
--
Market Capitalization281.08M52-Week High9.3900052-Week Low1.09000Average Volume0.57MDividend Yield--P/E Ratio--What does the Stockal+Disclaimer.pdf do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
10 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Applied Therapeutics, Inc. (NASDAQ: APLT) SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an...
PR Newswire
1 year ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty...
Globe Newswire
1 year ago
Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones ...
Globe Newswire
1 year ago
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the Company), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of...
Globe Newswire
1 year ago
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-007 (...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$4.23
$-0.08
(-1.86%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.